Prospective, multicenter, open-label study to evaluate the efficacy of esmolol in the early identification of cardiovascular disorders induced by cirrhosis, diabetes mellitus, and cardiotoxic treatments. - CIBER-bB-ECHO

Consorcio Centro De Investigacion Biomedica En Red0 个研究点目标入组 1,000 人开始时间: 2024年6月21日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Age = 18 years., Absence of previous heart disease, defined as the absence of relevant cardiac structural alterations such as moderate or severe hypertrophy, altered segmental contraction, moderate or severe valvular heart disease, intraventricular obstructive gradient, or old myocardial infarction., Existence of at least an acceptable ultrasound window, allowing visualization of at least 14 of the 17 segments of the LV myocardium., Sinus rhythm, with basal heart rate above 50 bpm.

•Contraindication for the administration of esmolol (according to technical data sheet): a. Hypersensitivity to esmolol hydrochloride. b. Severe sinus bradycardia (HR < 50 bpm). c. 2nd or 3rd degree atrioventricular block without pacemaker. d. Cardiogenic shock, severe hypotension, or decompensated heart failure. e. Untreated pheochromocytoma. f. Acute asthmatic crisis. g. Concomitant intravenous administration or in the first 48 hours after administration of verapamil., Treatment with beta-blocking drugs (oral, topical or intravenous) in the last 7 days before the study., History of ventricular or supraventricular arrhythmias that preclude safe withdrawal of antiarrhythmic or braking therapy prior to esmolol administration., History of previous high-grade AV conduction disorder in patients without pacemakers., Severe asthma with bronchial hyperresponsiveness., Patients with acute infection., Participants in other clinical trials in the 30 days prior to the start of the study., Women who are pregnant, or plan to become pregnant, and women who are breastfeeding., Patients with limitation to follow the protocol for any cause.

发起方